Clinical trial
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory…
NCT00129766 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00129766 |
|---|---|
| Title | Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children |
| Official title | A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Respiratory Syncytial Virus Infections |
| Intervention type | Biological |
| Interventions | motavizumab (MEDI-524), palivizumab |
| Enrollment | 6,635 |
| Start date | Nov 1, 2004 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Aug 12, 2005 |
| Last update posted | Aug 28, 2013 |
| Countries | Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Chile, Czechia, Denmark, France, Germany, Greece and 12 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: